AbbVie Inc. (NYSE: ABBV) has remained a steady performer in the healthcare space. The company has managed to offset Humira’s expected decline with rapid growth from its next-generation immunology drugs. The stock trades near $228/share, up about 20% over the past year, reflecting confidence in its strong earnings visibility and reliable dividend stream.
Recently, AbbVie reported encouraging late-stage results for Rinvoq in treating ulcerative colitis and gained new regulatory approvals for Skyrizi across additional autoimmune conditions, further reinforcing its leadership in immunology. The company also completed its acquisition of Cerevel Therapeutics, expanding its neuroscience pipeline and showing a continued push to diversify beyond Humira and strengthen long-term growth.
This article explores where Wall Street analysts think AbbVie could trade by 2027. We have pulled together consensus price targets and valuation models to outline the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
AbbVie trades at about $228/share today. The average analyst price target is $237/share, which points to roughly 4% upside over the next year. Forecasts show a fairly tight range, signaling stable sentiment:
- High estimate: ~$284/share
- Low estimate: ~$184/share
- Median target: ~$242/share
- Ratings: 13 Buys, 5 Outperforms, 9 Holds, 1 Underperforms
Analysts generally view AbbVie as a steady earnings compounder rather than a high-growth story.
For investors, AbbVie appears fairly valued with modest upside potential. Its dependable dividend, strong cash flow, and resilient drug portfolio support long-term stability, even if share price gains stay limited in the near term.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
AbbVie: Growth Outlook and Valuation
AbbVie’s fundamentals remain solid and well-supported by its expanding immunology and neuroscience franchises:
- Revenue is projected to grow about 8% annually through 2027
- Operating margins are expected near 48%
- Shares trade around 15x forward earnings, below many large-cap healthcare peers
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 14.7x forward P/E suggests AbbVie could reach roughly $258/share by 2027.
- That implies about 13% total upside, or around 6% annualized returns.
These projections highlight a slow but steady compounding story, driven by stable margins, strong cash generation, and disciplined capital allocation.
For investors, AbbVie offers a reliable mix of dividend income and gradual earnings growth. Its valuation looks fair for a company with strong margins and one of the most consistent cash flow profiles in pharma.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
AbbVie’s transition away from Humira continues to progress better than expected. Newer immunology drugs, Skyrizi and Rinvoq, are driving strong prescription growth and are on track to exceed Humira’s peak revenue within the next few years.
The company also strengthened its neuroscience pipeline through the Cerevel Therapeutics acquisition, adding promising treatments for depression and Parkinson’s disease. Together, these moves position AbbVie for stable mid-single-digit earnings growth even as older drugs decline.
For investors, AbbVie’s growth engine is shifting smoothly toward durable franchises. The mix of expanding drug approvals and strong cash flow generation supports a long runway for dividends and modest capital gains.
Bear Case: Slower Growth and Patent Pressure
Even with these positives, AbbVie still faces execution risks. The company depends heavily on a few key therapies to drive most of its growth. If adoption of Skyrizi or Rinvoq slows, or if competitors introduce more effective treatments, revenue momentum could soften.
Patent expirations and rising biosimilar competition may also pressure pricing power in immunology and oncology.
For investors, AbbVie’s main risk is that growth could flatten once its current pipeline matures. Without meaningful new launches, the valuation could stay capped near current levels.
Outlook for 2027: What Could AbbVie Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests AbbVie could trade around $258/share by 2027, representing roughly 13% total upside or about 6% annualized returns.
That outlook assumes steady earnings growth, margin stability, and a fully ramped immunology portfolio. Stronger drug uptake or higher cost savings could lift returns modestly, while slower execution would likely limit gains.
For investors, AbbVie looks like a reliable long-term income compounder. The story is less about rapid expansion and more about maintaining stability, rewarding patient shareholders with dependable dividends and consistent value creation.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Click here to sign up for TIKR and get your free copy of TIKR’s 5 AI Compounders report today.
